Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F18%3AN0000010" target="_blank" >RIV/00209775:_____/18:N0000010 - isvavai.cz</a>

Result on the web

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209701/pdf/AMS-14-33992.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209701/pdf/AMS-14-33992.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5114/aoms.2018.79002" target="_blank" >10.5114/aoms.2018.79002</a>

Result language

angličtina

Original language name

Viral genome changes and the impact of viral genome persistence in myocardium of patients with inflammatory cardiomyopathy

Original language description

Introduction: Viral infections are considered the most frequent cause of myocarditis and dilated cardiomyopathy (DCM). Material and methods: We investigated the changes in viral presence and the impact of viral genome persistence in the myocardium on echocardiographic parameters, functional status and some laboratory parameters in a 6-month follow-up. Fifty-four patients with recent onset DCM, left ven-tricular ejection fraction < 40% and biopsy-proven myocarditis (> 14 mono-nuclear leukocytes/mm2 and/or > 7 T-lymphocytes/mm2) were enrolled. Polymerase chain reaction (PCR) was performed to detect pathogens in the myocardium. Patients were divided according to the administered therapy: standard heart failure medication (46 patients) and immunosuppressive therapy (8 patients). Results: In the standard heart failure medication group viral clearance was observed in 13 patients and viral persistence in 24 patients in the follow-up period. Comparing both groups, there was no statistically significant difference – LVEF improvement of 12.0 ± 11.4% vs. 18.3 ± 12.6%, decrease in NYHA class of 0.7 ± 0.7 vs. 1.0 ± 0.7, decline in NT-proBNP of 1335 ± 1933 ng/l vs. 1942 ± 3242 ng/l and decrease in infiltrating leukocytes of 11.1 ± 15.8 vs. 6.7 ± 23.0 cells/mm2 and T-lymphocytes of 5.8 ± 15.1 vs. 1.8 ± 10.9 cells/mm2 (all p = NS). A decrease in PCR positive patients from 37 to 29 was observed. The number of PVB19 positive PCR findings decreased from 5 to 4 in patients with immunosuppressive therapy. Conclusions: A decrease in the number of positive PCR findings in control endomyocardial biopsy was observed. Viral genome persistence was not associated with worse outcome in short-term follow-up.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Archives of Medical Science - Atherosclerotic Diseases

ISSN

2451-0629

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

6

Country of publishing house

PL - POLAND

Number of pages

9

Pages from-to

1245-1253

UT code for WoS article

000448045000005

EID of the result in the Scopus database

2-s2.0-85055781554